Short oral presentations – focus on science & industry

Wednesday 30 September 2015
C5, 3 hours

Organised by the FIP Industrial Pharmacy Section and the FIP SIGs on Drug Design and Discovery, Natural Products, Formulation Design and Pharmaceutical Technology, Pharmacokinetics/Pharmacodynamics & Systems Pharmacology, Translational Research and Individualised Medicines,Biotechnology, Analytical Sciences and Pharmaceutical Quality, Regulatory Sciences                                        


This session aims to stimulate pharmacists and pharmaceutical scientists to present their work in a short and concise way and get direct feedback from the panel of jury on different aspects of presentation: communication and presentations skills, material used for presentation etc. This session will provide an opportunity for pharmacists to show their research and help both presenters and audience to engage in discussion on the “hot topics” of pharmacy and how different research could be further utilised in different pharmacy practice settings.

Learning objectives

Knowledge-based session

At the conclusion of this session, participants will be able to:

  1. Describe some original pharmaceutical science & industry contributions.
  2. Compare the impact of these contributions based on their own experiences.
  3. Identify how to make a striking presentation in a short and concise way.
  4. List a number of initiatives undertaken by individual pharmacists and/or pharmacy organisations.


Chairs: Gabrielle Wiederkehr (FIP IPS, Switzerland) and Igor Linhares de Castro (FIP IPS, Brazil)

14:30 Introduction by the Chair

14:35 1) Implementation of a pharmacist-led pharmacogenomics service for community-based frail elderly

Kevin Bain (Tabula Rasa Healthcare, USA)

14:45 2) Drug quality and dissolution testing at all points in the supply chain: integration of scalable technology in the health system

Nga Ho (Boston University, USA)

14:55 3) Endangering lives for a few cents of profit: a counterfeit antimalarial medicine in Malawi contains not sulfadoxine/pyrimethamine but paracetamol or cotrimoxazole

Lutz Heide (University of Malawi, Malawi)

15:05 4) Development and implementation of a Master’s Degree (MS) in biotechnology innovation and regulation science (BIRS) in Africa

Karl Clase (Purdue University, USA)

15:15 5) Brand story of a leading G.I. product

Mandy Fan (Taipei Pharmacists Association, China Taiwan)

15:25 6) Influence of Korea-US FTA conclusion on Korean pharmaceutical industry

Seok Goo Chang (Korean Pharmaceutical Assocation, Republic of Korea)

15:35 7) Determination of in-vitro equivalence of BCS class 1 drugs: paracetamol, phenoxymethylpenicillin and metronidazole tablets available in Sri Lanka

Dhanusha Thambavita (University of Colombo, Sri Lanka)

15:45 Break

16:15 8) GMP assessment of Mongolian pharmaceutical manufacturers

Tsatsrai Ichnikhorloo (Fourth Health sector Development Project, Mongolia)

16:25 9) Prediction of drug clearance in elderly patients using the Simcyp geriatrics model

Manoranjenni Chetty (Simcyp, UK)

16:35 10) Quantitative effect of CYP2C19 and CYP2C9 genotype on concentration prediction of valproate in epileptic patients

Dechun Jang (XuanWu Hospital of Capital Medical University, China)

16:45 11) Impact of SCN1A, ABCB1 and EPHX1 polymorphic variants in plasma carbamazepine concentrations and pharmacoresistance in Kosovar population

Armond Daci (University of Kosovo, Kosovo)

16:55 12) Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine

Deepak Kumar Mishara (ADINA Institute of Pharmaceutical Sciences, India)

17:05 13) Development of novel omega-3 polysaturated fatty acid derived agents that inhibit breast cancer growth in vivo

Tristan Rawling (University of Technology Sydney, Australia)

17:15 14) Label-free visualisation of islets markers and drugs in pancreas using high-resolution mass spectrometry imaging

Dhaka Ram Bandari ((Justus Liebig University, Germany)

17:25 Conclusion by the Chair